C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2016’, provides in depth analysis on C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted pipeline therapeutics.

The report provides comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects

The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

American Gene Technologies International Inc.

Calimmune, Inc.

ChemoCentryx, Inc.

Cytodyn Inc.

GlaxoSmithKline Plc

Pharis Biotec GmbH

Tobira Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) Overview 8

Therapeutics Development 9

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Stage of Development 9

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Therapy Area 10

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Indication 11

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Companies 14

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Products under Development by Universities/Institutes 17

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development 26

American Gene Technologies International Inc. 26

Calimmune, Inc. 27

ChemoCentryx, Inc. 28

Cytodyn Inc. 29

GlaxoSmithKline Plc 30

Pharis Biotec GmbH 31

Tobira Therapeutics, Inc. 32

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles 33

(cenicriviroc mesylate + efavirenz + lamivudine) - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

(cenicriviroc mesylate + evogliptin) - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

(cenicriviroc mesylate + lamivudine) - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

AG-1105 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

CAL-21 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

CAL-MGMT - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

CAL-X - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

CCL-14 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

cenicriviroc mesylate - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

DS-001 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

DS-004 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

DS-005 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

GSK-214096 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

PRO-140 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

RAP-103 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

VIP - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Projects 65

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products 68

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Featured News & Press Releases 69

Oct 20, 2016: Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting 69

Oct 13, 2016: bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials 70

Oct 06, 2016: CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 After Positive FDA Meeting 70

Oct 03, 2016: Tobira Therapeutics Announces Presentations Related to Cenicriviroc's Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting 70

Sep 12, 2016: Tobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin 71

Sep 07, 2016: Tobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee 72

Aug 23, 2016: Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study 72

Jul 26, 2016: First Patient Enrolled Under Newly Modified Protocol in CytoDyn’s Phase 3 PRO 140 Combination Study in HIV 73

Jul 25, 2016: Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year 74

Jul 21, 2016: CytoDyn Submits Orphan Drug Application to FDA for Pretreatment With PRO 140 of Treatment-Naïve HIV Patients 75

Jul 19, 2016: CytoDyn Submits Protocol for Phase 2b Trial for Treatment Naïve HIV Patients 76

Jun 27, 2016: Tobira’s Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH 77

Jun 22, 2016: ASM Microbe 2016 Presentation of Clinical Results From CytoDyn's Phase 2b Monotherapy Extension Study Now Available 77

Jun 17, 2016: CytoDyn's PRO 140 Phase 2b HIV Monotherapy Trial Findings to be Presented at ASM Microbe 2016 Conference on June 20 78

Jun 16, 2016: Tobira's Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology 78

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by American Gene Technologies International Inc., H2 2016 26

Pipeline by Calimmune, Inc., H2 2016 27

Pipeline by ChemoCentryx, Inc., H2 2016 28

Pipeline by Cytodyn Inc., H2 2016 29

Pipeline by GlaxoSmithKline Plc, H2 2016 30

Pipeline by Pharis Biotec GmbH, H2 2016 31

Pipeline by Tobira Therapeutics, Inc., H2 2016 32

Dormant Projects, H2 2016 65

Dormant Projects (Contd..1), H2 2016 66

Dormant Projects (Contd..2), H2 2016 67

Discontinued Products, H2 2016 68

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Top 10 Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports